Novartis AG (NYSE:NVS)
| 96.93 Delayed Data As of Jan 22 |  +0.05 / +0.05%Today’s Change | 69.18 Today|||52-Week Range 99.84 | +2.65% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $220.5B |
Company Description
Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Contact Information
Novartis AG Lichtstrasse 35 Basel Basel-stadt (basle Town) 4056 |
Employees
Shareholders
| Other institutional | 5.29% |
| Mutual fund holders | 3.82% |
| Individual stakeholders | -- |
Top Executives
| Vasant Narasimhan | Chief Executive Officer |
| Harry Werner Kirsch | Chief Financial Officer |
| Elizabeth Theophille | Chief Technology & Digital Officer |
| John Tsai | Chief Medical Officer |
| Klaus Moosmayer | Chief Ethics Risk & Compliance Officer |
